Olga Guryanova

Olga Guryanova, MD, Ph.D.

AST PROF

Department: MD-PHARMACOLOGY / THERAPEUTICS
Business Phone: (352) 294-8590
Business Email: oguryanova@ufl.edu

Teaching Profile

Courses Taught
2018-2021,2023
GMS6560 Molecules to Man: Past, Present and Future Therapeutic Strategies for Disease
2020-2023
GMS6001 Fundamentals of Biomedical Sciences I
2019-2021
GMS6530 Medical Pharmacology and Therapeutics II: Cardiovascular, Renal and Respiratory Systems
2019-2021
GMS6540 Medical Pharmacology and Therapeutics IV: Cancer, Antimicrobial and Antiparasitic Agents
2020-2022
PAS5026 Pharmacotherapeu 2
2020-2023
BMS6816 Cancer Bio Clin Oncol
2018-2022
DEN6262 Prin of Pharmacology
2018,2020-2023
GMS6009 Principles of Drug Action and Therapeutics
2018
GMS7980 Research for Doctoral Dissertation
2018
GMS7979 Advanced Research
2021-2023
GMS6421 Cell Biology
2021
GMS6504 Advanced Medical Pharmacology
2021-2023
GMS6065 Fundamentals of Cancer Biology
2021-2022
GMS6053 Cancer Biology and Therapeutics
2022-2023
MDU4002 Introduction to Medical Science Seminar 2

Research Profile

Olga Guryanova is an NIH-funded investigator with 15+ years of experience in translational cancer research. Her scientific career has been driven by a commitment to innovative studies into molecular mechanisms of chemotherapeutic resistance and rational strategies for cancer cell re-sensitization, with translational implications and a focus on precision oncology. After training at the Cleveland Clinic with Dr. Jeremy Rich, an expert in malignant brain tumors, she completed a postdoctoral fellowship at Memorial Sloan Kettering Cancer Center (MSKCC) under Dr. Ross Levine, a world-class authority in hematologic malignancies. Dr. Guryanova’s research has been published in top-tier journals such as Nature Medicine, Cancer Cell, and Clinical Cancer Research as a first and a senior author. She is currently an Assistant Professor and member of the University of Florida Health Cancer Center, where her laboratory is focused on delineating the mechanisms of the cross-talk between epigenetics and chromatin organization, and how these processes contribute to the development of myeloid malignancies such as acute myeloid leukemia (AML), resistance to therapies, and clonal evolution. Ultimately, Dr. Guryanova would like to harness this mechanistic understanding to develop improved therapeutic approaches for leukemia.

Publications

2022
Combination strategies to promote sensitivity to cytarabine-induced replication stress in acute myeloid leukemia with and without DNMT3A mutations.
Experimental hematology. 110:20-27 [DOI] 10.1016/j.exphem.2022.03.008. [PMID] 35306047.
2022
DNMT3A Harboring Leukemia-Associated Mutations Directs Sensitivity to DNA Damage at Replication Forks.
Clinical cancer research : an official journal of the American Association for Cancer Research. 28(4):756-769 [DOI] 10.1158/1078-0432.CCR-21-2863. [PMID] 34716195.
2021
HOXBLINC long non-coding RNA activation promotes leukemogenesis in NPM1-mutant acute myeloid leukemia.
Nature communications. 12(1) [DOI] 10.1038/s41467-021-22095-2. [PMID] 33782403.
2021
Repurposing Tranexamic Acid as an Anticancer Agent.
Frontiers in pharmacology. 12 [DOI] 10.3389/fphar.2021.792600. [PMID] 35095503.
2020
Alterations to DNMT3A in Hematologic Malignancies.
Cancer research. [DOI] 10.1158/0008-5472.CAN-20-3033. [PMID] 33087320.
2020
DNMT3A alterations associated with myeloid malignancies dictate differential responses to hypomethylating agents.
Leukemia research. 94 [DOI] 10.1016/j.leukres.2020.106372. [PMID] 32445940.
2019
Catalytically inactive Dnmt3b rescues mouse embryonic development by accessory and repressive functions.
Nature communications. 10(1) [DOI] 10.1038/s41467-019-12355-7. [PMID] 31558711.
2019
Disulfide bond-disrupting agents activate the tumor necrosis family-related apoptosis-inducing ligand/death receptor 5 pathway.
Cell death discovery. 5 [DOI] 10.1038/s41420-019-0228-9. [PMID] 31839995.
2018
Loss of Dnmt3a Immortalizes Hematopoietic Stem Cells In Vivo.
Cell reports. 23(1):1-10 [DOI] 10.1016/j.celrep.2018.03.025. [PMID] 29617651.
2017
FQI1: a transcription-methylation switch for cancer.
Oncotarget. 8(8):12536-12537 [DOI] 10.18632/oncotarget.15087. [PMID] 28177910.
2016
Defining ATM-Independent Functions of the Mre11 Complex with a Novel Mouse Model.
Molecular cancer research : MCR. 14(2):185-95 [DOI] 10.1158/1541-7786.MCR-15-0281. [PMID] 26538284.
2016
DNMT3A mutations promote anthracycline resistance in acute myeloid leukemia via impaired nucleosome remodeling.
Nature medicine. 22(12):1488-1495 [DOI] 10.1038/nm.4210. [PMID] 27841873.
2016
Dnmt3a regulates myeloproliferation and liver-specific expansion of hematopoietic stem and progenitor cells.
Leukemia. 30(5):1133-42 [DOI] 10.1038/leu.2015.358. [PMID] 26710888.
2015
CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative Neoplasms.
Cancer cell. 28(1):15-28 [DOI] 10.1016/j.ccell.2015.06.006. [PMID] 26175413.
2014
A WIMSical approach to decoding DNA methylation in myeloid leukemia.
Genome biology. 15(9) [PMID] 25315876.
2013
Advances in the development of animal models of myeloid leukemias.
Seminars in hematology. 50(2):145-55 [DOI] 10.1053/j.seminhematol.2013.03.027. [PMID] 24216171.
2013
Deletion of Asxl1 results in myelodysplasia and severe developmental defects in vivo.
The Journal of experimental medicine. 210(12):2641-59 [DOI] 10.1084/jem.20131141. [PMID] 24218140.
2013
Facilitates chromatin transcription complex is an “accelerator” of tumor transformation and potential marker and target of aggressive cancers.
Cell reports. 4(1):159-73 [DOI] 10.1016/j.celrep.2013.06.013. [PMID] 23831030.
2012
DNMT3A and stem cell function: new insights into old pathways.
Haematologica. 97(3) [DOI] 10.3324/haematol.2012.064410. [PMID] 22383741.
2012
IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype.
Nature. 483(7390):479-83 [DOI] 10.1038/nature10866. [PMID] 22343889.
2012
Platelet-derived growth factor receptors differentially inform intertumoral and intratumoral heterogeneity.
Genes & development. 26(11):1247-62 [DOI] 10.1101/gad.193565.112. [PMID] 22661233.
2011
Curaxins: anticancer compounds that simultaneously suppress NF-κB and activate p53 by targeting FACT.
Science translational medicine. 3(95) [DOI] 10.1126/scitranslmed.3002530. [PMID] 21832239.
2011
Deubiquitylase HAUSP stabilizes REST and promotes maintenance of neural progenitor cells.
Nature cell biology. 13(2):142-52 [DOI] 10.1038/ncb2153. [PMID] 21258371.
2011
L1CAM regulates DNA damage checkpoint response of glioblastoma stem cells through NBS1.
The EMBO journal. 30(5):800-13 [DOI] 10.1038/emboj.2011.10. [PMID] 21297581.
2011
Nonreceptor tyrosine kinase BMX maintains self-renewal and tumorigenic potential of glioblastoma stem cells by activating STAT3.
Cancer cell. 19(4):498-511 [DOI] 10.1016/j.ccr.2011.03.004. [PMID] 21481791.
2010
Cancer stem cells in glioblastoma–molecular signaling and therapeutic targeting.
Protein & cell. 1(7):638-55 [DOI] 10.1007/s13238-010-0078-y. [PMID] 21203936.

Grants

Sep 2021 ACTIVE
DNMT3A loss facilitates KMT2C-induced enhancer switching in myeloid malignancies
Role: Co-Investigator
Funding: EVANS MEDICAL FOU
Jul 2020 – Jun 2022
Novel combinatorial treatment approaches to augment sensitivity to cytarabine in acute myeloid leukemia with DNMT3A mutations
Role: Principal Investigator
Funding: OCALA ROYAL DAMES FOR CANCER RESEARCH
Apr 2020 – Mar 2022
Bad Blood: How Mutations in the Blood System Contribute to Aggressive Phenotype of Solid Tumors
Role: Principal Investigator
Funding: UF FOUNDATION
Jul 2019 ACTIVE
The role of DNMT3A mutations in clonal heterogeneity and evolution of hematopoiesis
Role: Principal Investigator
Funding: NATL INST OF HLTH NIDDK
Apr 2018 – May 2022
Ionizing radiation induced hematological malignancies
Role: Project Manager
Funding: NATL INST OF HLTH NCI
Nov 2017 – Oct 2022
The Harry T. Mangurian, Jr. Foundation – Support for the Study of Therapy Resistant Leukemia
Role: Co-Project Director/Principal Investigator
Funding: UF FOUNDATION via HARRY T MANGURIAN JR FOU
Sep 2016 – Aug 2020
Biologic and therapeutic relevance of DNMT3A mutations in acute myeloid leukemia
Role: Principal Investigator
Funding: NATL INST OF HLTH NCI
Feb 2015 ACTIVE
UF Health Cancer Center Pilot Project Grants funded through the Florida Consortium of National Cancer Institute Centers Program
Role: Project Manager
Funding: UF HEALTH SHANDS HOSPITAL

Contact Details

Phones:
Business:
(352) 294-8590
Emails:
Business:
oguryanova@ufl.edu
Addresses:
Business Mailing:
PO Box 100267
GAINESVILLE FL 32610
Business Street:
2033 MOWRY RD
GAINESVILLE FL 32610